These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 36857860)

  • 41. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunological imprinting of humoral immunity to SARS-CoV-2 in children.
    Dowell AC; Lancaster T; Bruton R; Ireland G; Bentley C; Sylla P; Zuo J; Scott S; Jadir A; Begum J; Roberts T; Stephens C; Ditta S; Shepherdson R; Powell AA; Brent AJ; Brent B; Baawuah F; Okike I; Beckmann J; Ahmad S; Aiano F; Garstang J; Ramsay ME; Azad R; Waiblinger D; Willett B; Wright J; Ladhani SN; Moss P
    Nat Commun; 2023 Jun; 14(1):3845. PubMed ID: 37386081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID-19 vaccine booster shot against Omicron SARS-CoV-2 infection.
    Wang B; Yang W; Tong Y; Sun M; Quan S; Zhu J; Zhang Q; Qin Z; Ni Y; Zhao Y; Wang K; Zhang C; Zhang Y; Wang Z; Song Z; Liu H; Fang H; Kong Z; Ding C; Guo W
    J Med Virol; 2023 Nov; 95(11):e29219. PubMed ID: 37966997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
    Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
    J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
    Luczkowiak J; Rivas G; Labiod N; Lasala F; Rolo M; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Med Virol; 2023 Jan; 95(1):e28268. PubMed ID: 36319593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Imprinted Immunity Induced by mRNA Vaccination in an Experimental Animal Model.
    Fujita S; Uriu K; Pan L; Nao N; Tabata K; Kishimoto M; Itakura Y; Sawa H; Kida I; Tamura T; ; Fukuhara T; Ito J; Matsuno K; Sato K
    J Infect Dis; 2023 Oct; 228(8):1060-1065. PubMed ID: 37369369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant.
    Heinen N; Marheinecke CS; Bessen C; Blazquez-Navarro A; Roch T; Stervbo U; Anft M; Plaza-Sirvent C; Busse S; Klöhn M; Schrader J; Vidal Blanco E; Urlaub D; Watzl C; Hoffmann M; Pöhlmann S; Tenbusch M; Steinmann E; Todt D; Hagenbeck C; Zimmer G; Schmidt WE; Quast DR; Babel N; Schmitz I; Pfänder S
    Front Immunol; 2022; 13():1062210. PubMed ID: 36618413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
    Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
    J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
    Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
    Front Immunol; 2022; 13():899972. PubMed ID: 35693807
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination.
    Kurahashi Y; Furukawa K; Sutandhio S; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
    J Infect Dis; 2022 Oct; 226(8):1391-1395. PubMed ID: 35512332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A potential association between obesity and reduced effectiveness of COVID-19 vaccine-induced neutralizing humoral immunity.
    Faizo AA; Qashqari FS; El-Kafrawy SA; Barasheed O; Almashjary MN; Alfelali M; Bawazir AA; Albarakati BM; Khayyat SA; Hassan AM; Alandijany TA; Azhar EI
    J Med Virol; 2023 Jan; 95(1):e28130. PubMed ID: 36068377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
    Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
    J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.